The original VK decision was not a good one. However, from my point of view, I am glad they did the work needed to decide not to procfeed. Some thinks simply cost money to get to the right place, but it would have been a lot better if that had not been needed.
Regards the quarterly - still showing steady progress without any input from Hepafat. They do mention that Hepafat has had 'interest' in clinical trials from several current customers. Once they get some going revenue will pick up quite quickly wothout much increase in cost.
RHT Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
